12:00 AM
 | 
Jun 20, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALKS 4230: Phase I started

Alkermes began a dose-escalation, dose-expansion Phase I trial to evaluate IV ALKS 4230 in patients who are refractory or intolerant to established therapies.

Alkermes...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >